• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

主要桦树花粉过敏原的天然加工 T 细胞激活肽。

Naturally processed T cell-activating peptides of the major birch pollen allergen.

机构信息

Christian Doppler Laboratory for Allergy Diagnosis and Therapy, Department of Molecular Biology, University of Salzburg, Salzburg, Austria.

出版信息

J Allergy Clin Immunol. 2010 Mar;125(3):711-8, 718.e1-718.e2. doi: 10.1016/j.jaci.2009.10.052. Epub 2010 Feb 4.

DOI:10.1016/j.jaci.2009.10.052
PMID:20132976
Abstract

BACKGROUND

Although antigen processing and presentation of allergens to CD4(+)T lymphocytes are key events in the pathophysiology of allergic disorders, they still remain poorly understood.

OBJECTIVE

To investigate allergen processing and presentation by dendritic cells using the major birch pollen allergen Bet v 1 as a model.

METHODS

Endolysosomal extracts of dendritic cells derived from patients with birch pollen allergy were used to digest Bet v 1. Dendritic cells were pulsed with Bet v 1, and peptides were eluted from MHC class II molecules. Peptides obtained by either approach were sequenced by tandem mass spectrometry. Bet v 1-specific T-cell cultures were stimulated with HLA-DR-eluted Bet v 1-derived peptides. Bet v 1-specific T-cell lines were generated from each patient and analyzed for epitope recognition.

RESULTS

A high proportion of Bet v 1 remained intact for a long period of endolysosomal degradation. The peptides that appeared early in the degradation process contained frequently recognized T-cell epitopes. Bet v 1-derived peptides eluted from MHC class II molecules corresponded to those generated by endolysosomal degradation, matched known T-cell epitopes, and showed T cell-activating capacity. The Bet v 1-specific T-cell line of each individual harbored T cells reactive with peptides located within the MHC class II-eluted Bet v 1-derived sequences demonstrating their occurrence in vivo.

CONCLUSION

We report for the first time how epitopes of allergens are generated and selected for presentation to T lymphocytes. The limited susceptibility of Bet v 1 to endolysosomal processing might contribute to its high allergenic potential.

摘要

背景

尽管过敏原向 CD4(+)T 淋巴细胞的抗原加工和呈递是过敏症病理生理学的关键事件,但它们仍然知之甚少。

目的

以主要桦树花粉过敏原 Bet v 1 为模型,研究树突状细胞中的过敏原加工和呈递。

方法

使用来自桦树花粉过敏患者的树突状细胞的内溶酶体提取物消化 Bet v 1。用 Bet v 1 脉冲处理树突状细胞,并从 MHC Ⅱ类分子洗脱肽。通过串联质谱法对两种方法获得的肽进行测序。用 HLA-DR 洗脱的 Bet v 1 衍生肽刺激 Bet v 1 特异性 T 细胞培养物。从每位患者中生成 Bet v 1 特异性 T 细胞系,并分析其表位识别。

结果

内溶酶体降解过程中很长一段时间内,Bet v 1 的很大一部分保持完整。在降解过程中早期出现的肽含有经常被识别的 T 细胞表位。从 MHC Ⅱ类分子洗脱的 Bet v 1 衍生肽与通过内溶酶体降解产生的肽相对应,与已知的 T 细胞表位匹配,并具有 T 细胞激活能力。每个人的 Bet v 1 特异性 T 细胞系都含有与 MHC Ⅱ类洗脱的 Bet v 1 衍生序列中定位的肽反应的 T 细胞,证明它们在体内发生。

结论

我们首次报告了过敏原表位如何被生成和选择以呈递给 T 淋巴细胞。Bet v 1 对内溶酶体处理的有限易感性可能有助于其高致敏性。

相似文献

1
Naturally processed T cell-activating peptides of the major birch pollen allergen.主要桦树花粉过敏原的天然加工 T 细胞激活肽。
J Allergy Clin Immunol. 2010 Mar;125(3):711-8, 718.e1-718.e2. doi: 10.1016/j.jaci.2009.10.052. Epub 2010 Feb 4.
2
Recognition of T cell epitopes unique to Cha o 2, the major allergen in Japanese cypress pollen, in allergic patients cross-reactive to Japanese cedar and Japanese cypress pollen.在对日本柳杉花粉和日本扁柏花粉交叉反应的过敏患者中识别日本扁柏花粉主要过敏原Cha o 2特有的T细胞表位。
Allergol Int. 2009 Jun;58(2):237-45. doi: 10.2332/allergolint.08-OA-0027. Epub 2009 Mar 25.
3
Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.桦树花粉免疫治疗导致调节性 T 细胞的差异诱导和辅助性 T 细胞免疫偏离的延迟。
J Immunol. 2010 Feb 15;184(4):2194-203. doi: 10.4049/jimmunol.0901379. Epub 2010 Jan 4.
4
Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly.通过合理的序列重组获得的主要桦树花粉过敏原 Bet v 1 的低变应原性衍生物。
J Allergy Clin Immunol. 2010 Nov;126(5):1024-31, 1031.e1-8. doi: 10.1016/j.jaci.2010.05.023. Epub 2010 Jul 16.
5
Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season.在桦树花粉季节,桦树过敏患者体内的CD4CD25调节性T细胞对Th2细胞因子的抑制功能存在缺陷。
Clin Exp Allergy. 2004 Sep;34(9):1364-72. doi: 10.1111/j.1365-2222.2004.02067.x.
6
Bet v 1 and its homologous food allergen Api g 1 stimulate dendritic cells from birch pollen-allergic individuals to induce different Th-cell polarization.Bet v 1 及其同源食物过敏原 Api g 1 可刺激桦树花粉过敏个体的树突状细胞,诱导不同的 Th 细胞极化。
Allergy. 2010 Nov;65(11):1388-96. doi: 10.1111/j.1398-9995.2010.02407.x.
7
Immunological characteristics of subjects with asymptomatic skin sensitization to birch and grass pollen.对桦树和草花粉无症状皮肤致敏受试者的免疫学特征
Clin Exp Allergy. 2006 Mar;36(3):283-92. doi: 10.1111/j.1365-2222.2006.02435.x.
8
Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy.用于桦树花粉免疫疗法的完整变应原疫苗与市售变应原提取物产品的致敏性和免疫原性比较
Clin Exp Allergy. 2007 Apr;37(4):564-71. doi: 10.1111/j.1365-2222.2007.02687.x.
9
A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation.主要桦树花粉过敏原的低变应原性变异体在抗原加工和 T 细胞激活方面表现出明显的特征。
Allergy. 2012 Nov;67(11):1375-82. doi: 10.1111/all.12016. Epub 2012 Sep 13.
10
Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.奥拉里桦树,一种用于桦树花粉引起的过敏性鼻炎舌下免疫治疗的重组主要桦树花粉过敏原片剂。
Curr Opin Investig Drugs. 2010 May;11(5):586-96.

引用本文的文献

1
To stay or not to stay intact as an allergen: the endolysosomal degradation assay used as tool to analyze protein immunogenicity and cell epitopes.作为变应原是否保持完整:用作分析蛋白质免疫原性和细胞表位的工具的内溶酶体降解测定法。
Front Allergy. 2024 Jul 12;5:1440360. doi: 10.3389/falgy.2024.1440360. eCollection 2024.
2
Designing a T-cell epitope-based vaccine using in silico approaches against the Sal k 1 allergen of Salsola kali plant.利用计算机方法设计针对盐角草 Sal k 1 过敏原的 T 细胞表位疫苗。
Sci Rep. 2024 Feb 29;14(1):5040. doi: 10.1038/s41598-024-55788-x.
3
Structural and Immunologic Properties of the Major Soybean Allergen Gly m 4 Causing Anaphylaxis.
引起过敏反应的大豆主要过敏原 Gly m 4 的结构和免疫特性。
Int J Mol Sci. 2022 Dec 6;23(23):15386. doi: 10.3390/ijms232315386.
4
New Therapeutic Approaches for Allergy: A Review of Cell Therapy and Bio- or Nano-Material-Based Strategies.过敏的新治疗方法:细胞疗法及基于生物或纳米材料策略的综述
Pharmaceutics. 2021 Dec 14;13(12):2149. doi: 10.3390/pharmaceutics13122149.
5
Nanotechnology-Based Vaccines for Allergen-Specific Immunotherapy: Potentials and Challenges of Conventional and Novel Adjuvants under Research.基于纳米技术的变应原特异性免疫疗法疫苗:研究中传统佐剂和新型佐剂的潜力与挑战
Vaccines (Basel). 2020 May 20;8(2):237. doi: 10.3390/vaccines8020237.
6
Effect of structural stability on endolysosomal degradation and T-cell reactivity of major shrimp allergen tropomyosin.结构稳定性对主要虾过敏原原肌球蛋白的内溶酶体降解及T细胞反应性的影响
Allergy. 2020 Nov;75(11):2909-2919. doi: 10.1111/all.14410. Epub 2020 Jun 18.
7
Applying MAPPs Assays to Assess Drug Immunogenicity.应用 MAPP 分析评估药物免疫原性。
Front Immunol. 2020 Apr 21;11:698. doi: 10.3389/fimmu.2020.00698. eCollection 2020.
8
CD4 T immunogenicity of the . secreted products..分泌产物的CD4 T免疫原性。
NPJ Vaccines. 2020 Mar 20;5:25. doi: 10.1038/s41541-020-0171-z. eCollection 2020.
9
Major Histocompatibility Complex Binding, Eluted Ligands, and Immunogenicity: Benchmark Testing and Predictions.主要组织相容性复合物结合、洗脱配体和免疫原性:基准测试和预测。
Front Immunol. 2020 Feb 5;10:3151. doi: 10.3389/fimmu.2019.03151. eCollection 2019.
10
Structural Bases for the Allergenicity of Fra a 1.02 in Strawberry Fruits.草莓果实中 Fra a 1.02 变应原性的结构基础。
J Agric Food Chem. 2020 Sep 30;68(39):10951-10961. doi: 10.1021/acs.jafc.9b05714. Epub 2020 Jan 3.